Excess relative risk estimates for Hodgkin lymphoma, mature B-cell neoplasms, mature T-cell neoplasms and precursor lymphoid neoplasms, LSS, 1950 to 1994
| . | Cases . | n . | ERR at 1Gy . | RR at 1Gy . | Model . |
|---|---|---|---|---|---|
| Hodgkin lymphoma | All | 15 | 0.61 (less than −0.09, 7.17) | 1.61 | Linear, high-dose adjustment |
| All non-Hodgkin lymphoid neoplasms | All | 479 | 0.54 (0.14, 1.09) | 1.54 | Linear, high-dose adjustment Male ERR (0.95) >Female ERR (0.05); ERR decreasing with increasing attained age |
| HV | 375 | 0.50 (0.06, 1.10) | 1.50 | Linear, high-dose adjustment | |
| Mature B-cell neoplasms | All | 319 | 0.04 (-0.24, 0.52) | 1.04 | Linear, high-dose adjustment |
| HV | 242 | 0.07 (NA, 0.69) | 1.07 | Linear | |
| PCM | All | 124 | −0.02 (less than −0.23, 0.62) | 0.08 | Linear |
| HV | 54 | 0.36 (−0.28, 1.96) | 1.36 | Linear, high-dose adjustment | |
| DLBCL | All | 116 | 0.14 (less than −0.18, 1.07) | 1.14 | Linear |
| Others | All | 79 | 0.42 (−0.30, 1.95) | 1.42 | Linear, high-dose adjustment |
| Mature T-cell and NK-cell neoplasms | All | 108 | −0.19 (NA, 0.78) | 0.81 | Linear |
| HV | 98 | −0.18 (NA, 10.84) | 0.82 | Linear | |
| ATLL | All | 32 | −0.30 (NA, 1.19) | 0.70 | Linear, among Nagasaki subjects |
| HV | 23 | −0.30 (NA, 1.01) | 0.70 | Linear, among Nagasaki subjects | |
| Others | All | 70 | 0.42 (less than -0.24, 2.21) | 1.42 | Linear, high-dose adjustment |
| Precursor cell neoplasms | All | 30 | Male: (L) 6.43 (0.96, 25.4), (Q) 48.6 (9.07, 330); Female: (L) 6.43 (0.96, 25.4) | Male: 56 Female: 7.43 | Male: Linear-quadratic (LQ). Female: Linear (L), high-dose adjustment; ERR decreasing with increasing attained age |
| Lymphoid neoplasms, NOS | All | 81 | 0.48 (−0.22, 1.79) | 1.48 | Linear, high-dose adjustment |
| . | Cases . | n . | ERR at 1Gy . | RR at 1Gy . | Model . |
|---|---|---|---|---|---|
| Hodgkin lymphoma | All | 15 | 0.61 (less than −0.09, 7.17) | 1.61 | Linear, high-dose adjustment |
| All non-Hodgkin lymphoid neoplasms | All | 479 | 0.54 (0.14, 1.09) | 1.54 | Linear, high-dose adjustment Male ERR (0.95) >Female ERR (0.05); ERR decreasing with increasing attained age |
| HV | 375 | 0.50 (0.06, 1.10) | 1.50 | Linear, high-dose adjustment | |
| Mature B-cell neoplasms | All | 319 | 0.04 (-0.24, 0.52) | 1.04 | Linear, high-dose adjustment |
| HV | 242 | 0.07 (NA, 0.69) | 1.07 | Linear | |
| PCM | All | 124 | −0.02 (less than −0.23, 0.62) | 0.08 | Linear |
| HV | 54 | 0.36 (−0.28, 1.96) | 1.36 | Linear, high-dose adjustment | |
| DLBCL | All | 116 | 0.14 (less than −0.18, 1.07) | 1.14 | Linear |
| Others | All | 79 | 0.42 (−0.30, 1.95) | 1.42 | Linear, high-dose adjustment |
| Mature T-cell and NK-cell neoplasms | All | 108 | −0.19 (NA, 0.78) | 0.81 | Linear |
| HV | 98 | −0.18 (NA, 10.84) | 0.82 | Linear | |
| ATLL | All | 32 | −0.30 (NA, 1.19) | 0.70 | Linear, among Nagasaki subjects |
| HV | 23 | −0.30 (NA, 1.01) | 0.70 | Linear, among Nagasaki subjects | |
| Others | All | 70 | 0.42 (less than -0.24, 2.21) | 1.42 | Linear, high-dose adjustment |
| Precursor cell neoplasms | All | 30 | Male: (L) 6.43 (0.96, 25.4), (Q) 48.6 (9.07, 330); Female: (L) 6.43 (0.96, 25.4) | Male: 56 Female: 7.43 | Male: Linear-quadratic (LQ). Female: Linear (L), high-dose adjustment; ERR decreasing with increasing attained age |
| Lymphoid neoplasms, NOS | All | 81 | 0.48 (−0.22, 1.79) | 1.48 | Linear, high-dose adjustment |
ERR, excess relative risk; RR, relative risk (calculated from ERR by using the definition ERR = RR - 1); HV, histologically verified; NA, not available; PCM, plasma cell myeloma; DLBCL, diffuse large B-cell lymphoma; ATLL, adult T-cell leukemia/lymphoma.